Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.

NCT06856928 | Not Yet Recruiting FDA Drug

• 1 other identifier: 24-1896
• Study Type: observational
• Target: 16
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake. Researchers will examine two groups: one just starting AOMs and another that has already achieved significant weight loss and maintained it. By conducting meal challenges at different stages of medication use, the study will assess feasibility of the methods and gather preliminary data to design a larger, future study.

Conditions

Obesity; Drug

Keywords

appetite-related hormones; appetite; metabolites

Outcome Measures

Primary Outcomes (3)

• Participant Recruitment

  Number of participants recruited for the study.

  6-10 weeks

• Meal test tolerability

  Number or participants able to tolerate and complete the test meal.

  6-10 weeks

• Rate of protocol completion

  Percentage of participants enrolled that complete the protocol

  6-10 weeks

Secondary Outcomes (17)

• Change in peptide YY (pg/ml)

  6-10 weeks

• Change in Glucagon Like Peptide-1 (pg/mL)

  6-10 weeks

• Change in leptin (ng/mL)

  6-10 weeks

• Change in insulin (uIU/mL)

  6-10 weeks

• Change in Glucagon (pg/mL)

  6-10 weeks

Study Arms (2)

Early Group

Participants in the early group are individuals that have established agreements with their clinical providers to begin treatment with semaglutide or tirzepatide as part of their ongoing weight management strategy. These participants will complete a meal challenge before they start the medication and 6 weeks after starting medication.

Other: Meal Challenge

Late Group

Participants in the late group are individuals that have lost \>12% of their body weight on either semaglutide or tirzepatide and are still taking the medication. These participants will complete a meal challenge before they discontinue medication and 3 weeks after discontinuing the medication.

Other: Meal Challenge

Interventions

Meal Challenge OTHER

The meal challenge scheduled for 4-6 days after the patient's last injection. The study team will insert an indwelling venous catheter into the participant's forearm for serial blood draws. Immediately prior to the meal, participants will consume 1500 mg of acetaminophen (off-label) to facilitate the analysis of gastric emptying. The participant will then begin the meal challenge by eating the test meal, a breakfast casserole, containing 33% of their current resting energy expenditure needs estimated by Mifflin-ST Jeor equation with a composition of 50% carbohydrate, 30% fat and 20% protein. Participants must completely consume the test meal within 25 minutes of initiating the meal. Participants will fill out behavioral questionnaires after consuming the test meal. After the 2-hour blood draw period, participants will be dismissed. Blood will be drawn prior to the meal and at 5, 10, 15, 30, 60, 90, and 120 minutes after initiating the meal.

Early Group; Late Group

Eligibility Criteria

• Age: 25 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Potential participants are residents of the Denver metropolitan area who have either: 1. Had or has obesity and experienced significant weight loss while taking semaglutide or tirzepatide, or 2. Has obesity and has established agreements with their healthcare providers to begin treatment with semaglutide or tirzepatide.

You may qualify if:

• Adult males and females with a BMI of 30-45 kg/m2 (early group), or a BMI of 30-45 kg/m2 prior to weight loss achieved through medication (late group)
• Age, 25-60 years old
• Passing medical and physical screening, and analysis of blood and urine screening samples
• Anticipated to start or are already prescribed AOMs (semaglutide or tirzepatide)
• months weight stable (early group) or 3 months weight stable at current weight (late group)
• Women of reproductive age must be using an effective form of contraception

You may not qualify if:

• Diagnosed with type 1 or 2 diabetes
• Smoker
• Previous surgical treatment or device-based therapy for obesity
• Chronic or acute pancreatitis
• Clinically significant gastric emptying abnormality
• Uncontrolled hypertension or hypo/hyperthyroidism
• Cardiovascular event 3 months within screening
• Acute or chronic hepatitis
• Inability to tolerate beef, eggs, and cheese
• Women who are pregnant
• Women who are nursing

Sponsors & Collaborators

• University of Colorado, Denver: lead

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Post Doctoral Fellow

Study Record Dates

• First Submitted: February 13, 2025
• First Posted: March 4, 2025
• Study Start: March 1, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2027
• Last Updated: March 4, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share